Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

820
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
820
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

509
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
509
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

559
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
559
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

572
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
572
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

565
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
565
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution01:25

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

225
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
225

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Serum chitotriosidase-1 (CHIT1) as candidate biomarker for mitochondriopathies.

Journal of neurology·2025
Same author

Dietary selective effects manifest in the human gut microbiota from species composition to strain genetic makeup.

Cell reports·2025
Same author

Bioavailability of EPA and DHA in humans - A comprehensive review.

Progress in lipid research·2024
Same author

Dietary selective effects manifest in the human gut microbiota from species composition to strain genetic makeup.

Cell reports·2024
Same author

User preference and patient benefits of a novel energy storing and return foot: A randomized, cross-over clinical trial.

Prosthetics and orthotics international·2024
Same author

Enhancement of Family-Centred Care Is Associated with a Reduction in Postmenstrual Age at Discharge in Preterm Infants.

Children (Basel, Switzerland)·2024

Related Experiment Video

Updated: Jan 9, 2026

Body Composition and Metabolic Caging Analysis in High Fat Fed Mice
10:28

Body Composition and Metabolic Caging Analysis in High Fat Fed Mice

Published on: May 24, 2018

16.2K

GLP-1 Receptor Agonists - Good for Body Weight, Bad for Micronutrient Status?

Felix Kerlikowsky1,2, Klaus Krämer2,3, Manfred Eggersdorfer2,4

  • 1Institute of Food Science and Human Nutrition, Leibniz University, Hannover, Germany.

Current Developments in Nutrition
|December 2, 2025
PubMed
Summary

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) effectively reduce calorie intake and promote weight loss. However, their use may increase the risk of micronutrient deficiencies, necessitating careful dietary management and further research.

Keywords:
GLP-1 receptor agonistsappetite suppressiondietary patternmicronutrient statusnutrient intakeweight loss

More Related Videos

Self-Administration of Drugs in Mouse Models of Feeding and Obesity
03:37

Self-Administration of Drugs in Mouse Models of Feeding and Obesity

Published on: June 8, 2021

5.1K
A RAPID Method for Blood Processing to Increase the Yield of Plasma Peptide Levels in Human Blood
11:36

A RAPID Method for Blood Processing to Increase the Yield of Plasma Peptide Levels in Human Blood

Published on: April 28, 2016

9.7K

Related Experiment Videos

Last Updated: Jan 9, 2026

Body Composition and Metabolic Caging Analysis in High Fat Fed Mice
10:28

Body Composition and Metabolic Caging Analysis in High Fat Fed Mice

Published on: May 24, 2018

16.2K
Self-Administration of Drugs in Mouse Models of Feeding and Obesity
03:37

Self-Administration of Drugs in Mouse Models of Feeding and Obesity

Published on: June 8, 2021

5.1K
A RAPID Method for Blood Processing to Increase the Yield of Plasma Peptide Levels in Human Blood
11:36

A RAPID Method for Blood Processing to Increase the Yield of Plasma Peptide Levels in Human Blood

Published on: April 28, 2016

9.7K

Area of Science:

  • Endocrinology
  • Nutrition Science
  • Pharmacology

Background:

  • Obesity is a growing global health crisis, projected to affect 24% of the world's population by 2035.
  • Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) offer a pharmacological approach to obesity management by mimicking the gut hormone GLP-1.
  • GLP-1 RAs reduce appetite and slow gastric emptying, leading to significant reductions in food and energy intake, surpassing previous pharmacotherapies.

Purpose of the Study:

  • To review current evidence on the impact of GLP-1 RAs on dietary patterns and micronutrient status.
  • To highlight the need for further research into the long-term nutritional consequences of GLP-1 RA therapy.

Main Methods:

  • A comprehensive literature search was conducted across major databases including PubMed/Medline, Scopus, Cochrane Databases, Google Scholar, Web of Science, and Embase.
  • Publications were limited to peer-reviewed articles in English, with data searched up to June 2025.

Main Results:

  • GLP-1 RA treatment can decrease energy intake by up to 40%, resulting in substantial weight loss compared to lifestyle interventions.
  • Concerns exist regarding potential micronutrient deficiencies due to reduced food consumption, particularly in individuals with obesity.
  • Professional dietary counseling is crucial to ensure adequate intake of nutrient-dense, protein-rich foods and prevent muscle mass loss.

Conclusions:

  • The widespread use of GLP-1 RAs necessitates attention to potential micronutrient deficiencies, especially in obese populations already at higher risk.
  • Systematic investigation into the long-term nutritional effects of GLP-1 RAs, focusing on micronutrient status, is required.
  • Supervision and dietary guidance are essential for individuals using GLP-1 RAs to mitigate nutritional risks.